Trial Profile
A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Fluorocyclopentenylcytosine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Rexahn Pharmaceuticals
- 22 Jan 2019 According to a Rexahn Pharmaceuticals media release, the company expects to complete the study enrollment and to report additional efficacy data later this year.
- 22 Jan 2019 Preliminary Data (N=24) presented in a Rexahn Pharmaceuticals Media Release.
- 19 Jan 2019 Preliminary results (n=21, data cut off: 21 Sep 2018) presented at the 2019 Gastrointestinal Cancers Symposium